Chadwick Mills

Chadwick focuses on corporate and securities law, and he regularly acts as outside corporate counsel to public life sciences companies. Chad provides ongoing compliance and strategic advice to biotechnology, pharmaceutical and device companies and their boards of directors on a wide range of securities, corporate and investor outreach matters, including financial reporting and disclosure issues, shareholder engagement and activism, securities offerings and corporate governance matters, in each case based on his extensive experience in the public life sciences space.

Chad has worked with or served as primary outside counsel to numerous current and former public life sciences clients, including: AcelRx Pharmaceuticals, BioMarin Pharmaceutical, Cerus Corporation, Conor Medsystems, Exelixis, Geron Corporation, GTx, Jazz Pharmaceuticals, Kosan Biosciences, Medivation, Molecular Devices, Rigel Pharmaceuticals, Seattle Genetics and Threshold Pharmaceuticals.

Chad has represented issuers in more than 30 public company financings and initial public offerings during the past five years, including:

* BioMarin Pharmaceutical in its $720 million public offering of common stock

* Seattle Genetics in its $552 million public offering of common stock

* Jazz Pharmaceuticals in its $575 million aggregate principal amount of exchangeable senior notes

* Multiple other issuers in public offerings and private placements of equity and convertible debt securities